News

Recursion Pharmaceuticals stock has had a difficult run over the past several years, and the current valuation checks lean toward the shares looking expensive rather than like a clear bargain. Over the last 5 years, Recursion Pharmaceuticals has declined about 87%, which puts a clear focus on whether the current share price is aligned with the business outlook. The upcoming August 5 earnings call and business update can help shape expectations around Recursion Pharmaceuticals' ability to...

The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $2.97, representing a -2.62% change from its previous close.

In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $3.01, denoting a +1.69% move from the preceding trading day.

In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.34, indicating a +1.21% shift from the previous trading day.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Best Penny Stocks to Invest In According to Billionaires. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a biotechnology company that is building an AI-native discovery platform to industrialize drug discovery. Although still in the clinical stage, the company generates much of its revenue from key partnerships and collaborations with […]

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.72, moving 3.13% from the previous trading session.

Recursion Pharmaceuticals has been trying to rebuild momentum after a steep five year decline in shareholder returns, yet its current checks still point to a stock that screens as expensive rather than clearly cheap. Over the past 5 years, Recursion Pharmaceuticals shareholders have seen the stock decline about 90%, which puts extra focus on whether recent optimism is supported by today’s valuation. Progress with the AI driven drug discovery platform and clinical data for REC-4881 can...

Two stocks that have fallen out of favor and one hot stock that was one of Thursday's biggest losers were on the Ark Invest founder's shopping list.

Cathie Wood Loads Up on AI Winners as She Cuts Roku and China Exposure

Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from Silicon Valley. Biotechnology has spent decades producing breakthrough medicines, yet drug development has remained painfully slow, often taking 10 to 15 years while roughly 90% of candidates never reach approval. AI is beginning to change that equation. By ... AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity

Recursion Pharmaceuticals is trying to prove that AI’s next big winner can also come from biotech, and not just from the tech sector.

The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $3.18, representing a -3.34% change from its previous close.

X-Energy Inc. (NASDAQ:XE) is one of the 10 Stocks Stealing the Spotlight from Wall Street Giants. X-Energy saw its share prices increase by 13.50 percent on Monday to end at $21.10 apiece, mirroring the broader market optimism and Cathie Wood’s increased exposure to its stock. Last week, Wood’s global asset management, ARK Invest, announced that […]

Recursion Pharmaceuticals (RXRX) is back in focus as investors weigh fresh updates on its AI-driven drug discovery platform, along with progress in key clinical assets REC-1245 and REC-4881 and related regulatory discussions. See our latest analysis for Recursion Pharmaceuticals. At a share price of US$3.15, Recursion’s 30 day share price return of 3.28% contrasts with a year to date share price decline of 25% and a 1 year total shareholder return decline of 35.98%. This suggests recent...

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.06, moving 5.12% from the previous trading session.

Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

In recent days, Recursion Pharmaceuticals reported positive early clinical data and advances in its AI-driven drug discovery pipeline, alongside a narrower-than-expected first-quarter EPS loss and revenue that surpassed expectations, while also filing Form 144 notices for planned insider share sales and issuing multi-year RSU awards to new employees. Together, these developments highlight operational discipline, an extended cash runway into early 2028, and growing reliance on AI tools to...

Recursion Pharmaceuticals (NasdaqGS:RXRX) reported positive early clinical data from its AI driven drug discovery programs. The company highlighted progress in oncology and rare disease candidates in its latest pipeline update. The news focuses on clinical and platform milestones rather than regular earnings or compensation events. Recursion Pharmaceuticals is drawing attention as it pairs artificial intelligence with drug discovery, and its recent clinical update adds fresh detail to that...

Formerly known as Verge Genomics, the new Verge Labs will help pharma and biotech partners match potential brain drugs to patients who best benefit from them.

With an upside potential of 99.1% and a relative strength index (RSI) of 33.8, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands out as one of the notable oversold play in the AI sector. While analyst support remains strong, the stock is currently lacking investor confidence. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) fell to a new 52-week low of $2.85 […]

Recursion Pharmaceuticals (RXRX) has been drawing investor attention after recent trading shifts, with the stock closing at US$3.01 and showing mixed performance over the past week, month, and past three months. See our latest analysis for Recursion Pharmaceuticals. Recent trading has been choppy, with the 1 day share price return down 3.22% and the 30 day share price return down 14.24%, while the 1 year total shareholder return has declined 26.23%. This may indicate fading momentum as...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the 10 Best Penny Stocks to Buy for Long Term. On May 14, 2026, Morgan Stanley raised the firm’s price target on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) to $5.50 from $5 and kept an Equal Weight rating on the shares. On May 6, 2026, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) reported […]

NVIDIA's latest 13F filing does not tell the story it seems to at first glance. The apparent divergence in its CoreWeave and Nebius holdings is a prime example.

Recursion Pharmaceuticals (RXRX) has been in focus after fresh clinical updates on REC-4881 and REC-1245, along with ongoing FDA discussions for a potential registrational pathway, drew attention away from a mixed quarterly earnings print. See our latest analysis for Recursion Pharmaceuticals. At a share price of US$3.27, Recursion’s 30 day share price return of 2.51% sits against a 90 day share price decline of 17.84% and a 1 year total shareholder return of 25.51% loss. This suggests that...

Recursion Pharmaceuticals (NasdaqGS:RXRX) reported key clinical milestones across its AI-driven pipeline, including positive early data for REC-1245. The company initiated a new Phase 1 trial for REC-4539, expanding its early-stage clinical portfolio. REC-4881 achieved Phase 2 success in familial adenomatous polyposis, with active FDA engagement around a potential registrational pathway. Recursion Pharmaceuticals focuses on applying AI-driven drug discovery to build a diversified clinical...

The old healthcare model is breaking down.

Recursion Pharmaceuticals reports a narrower-than-expected Q1 loss, but revenues fall sharply as Roche collaboration income declines year over year.

Najat Khan: Good morning, everyone, and thank you for joining us. First, we're focusing on signal over noise, generating proof and proof points across our both wholly owned programs and our partner programs with the goal to showcase where AI can truly make a difference in creating value.

Recursion Pharmaceuticals (NASDAQ:RXRX) leadership used its latest earnings call to emphasize a sharper focus on translating artificial intelligence-enabled discovery into clinical and partnership “proof points,” while maintaining what it described as tighter financial discipline. CEO and President